December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
March 2025 in “Canadian dermatology today.” Clascoterone cream 1% is effective and well-tolerated for treating acne and other related conditions.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
August 2024 in “medRxiv (Cold Spring Harbor Laboratory)” Finasteride has various adverse effects, including sexual dysfunction and mental health issues, which vary by age and gender.
July 2024 in “Journal of Investigative Dermatology”
February 2024 in “Journal of Modern Oncology” Scalp cooling effectively prevents hair loss during chemotherapy in most cases.
December 2023 in “European journal of dermatology/EJD. European journal of dermatology” More effective treatments are needed for severe alopecia areata.
October 2023 in “Pharmacoepidemiology and Drug Safety” Most dermatology drugs in Denmark are used correctly, with few unusual patterns.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” Montelukast is linked to increased risks of suicidal thoughts and depression.
August 2021 in “Journal of the American Academy of Dermatology” The study evaluated how alopecia areata severity relates to its psychosocial effects on patients.
August 2022 in “Journal of The European Academy of Dermatology and Venereology” Mesotherapy with dutasteride effectively treats hair loss with manageable side effects.
October 2021 in “European urology open science” 21 citations
,
October 2023 in “Journal of Dermatological Treatment” Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
19 citations
,
April 2011 in “Headache The Journal of Head and Face Pain” Both topiramate and divalproex sodium effectively reduce migraine frequency and are generally well-tolerated.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
2 citations
,
October 2025 in “Frontiers in Medicine” Isotretinoin has many serious side effects, including some new ones, needing better safety measures and updated labels.
2 citations
,
July 2023 in “Journal of dermatology” Alopecia areata causes a significant economic burden in Japan, mainly due to productivity loss.
1 citations
,
October 2025 in “Frontiers in Immunology” Avacopan is generally safe, with some minor side effects like nausea and fatigue.
1 citations
,
February 2022 in “Lasers in Medical Science” Low-level laser therapy is about 80% effective in treating hair loss, with best results in males, those who use it for over a year, and those with scalp conditions like dandruff and rash.
1 citations
,
November 2020 in “Journal of The American Academy of Dermatology” Low input with cover crop optimizes yield and reduces greenhouse gas emissions.
February 2026 in “Skin Appendage Disorders” Scalp microinfusion with dutasteride is a safe and promising treatment for male hair loss.
January 2026 in “Andrology” PRP injections are safe but don't significantly improve Peyronie's Disease.
October 2025 in “EMJ Dermatology” GLP-1RA therapy may increase the risk of hair loss.
PRP injections with tadalafil and stretching safely improved Peyronie's symptoms but didn't significantly change curvature long-term.
August 2025 in “Journal of Cosmetic Dermatology” The dietary supplement AGA-P improves the effectiveness of hair loss treatments.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
August 2024 in “Journal of the American Academy of Dermatology” Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.
July 2024 in “The Journal of Dermatology” Severe alopecia areata in South Korea has a high treatment burden, with most patients needing multiple treatments and frequent doctor visits.